Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


International "Comparability" Of Regulatory Standards May Be FDA's Solution To GMP Oversight

This article was originally published in PharmAsia News

Executive Summary

FDA may begin to rely on foreign government oversight of manufacturing even if the standards for the overseas regulators do not exactly match those in the U.S

You may also be interested in...

Mylan Grabs More FDA Globalization Talent

Steve Lynn, director of CDER’s Office of Manufacturing and Product Quality, will take an executive global compliance position.

U.S. FDA Issues Warning Letters To Chinese Firms As Agency Tightens Foreign Field Inspections Program

The agency requests 16 more inspectors in China in an effort to boost enforcement and training.

Is Silence Golden For Brand Companies On Inspection Fees?

The inspection and establishment fee issue likely will remain a prickly subject for brand companies in the coming years, especially if a program is successfully launched for generics.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts